Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and whether oxytocin has similar effects on them or not.
The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and its underlying neural mechanisms and whether oxytocin has similar effects on them or not. A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A modified inequity decision-making task starts 45 minutes after treatment with behavioral (fairness rating, preference rating and the choice rate of unequal option) and fMRI data being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the task.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| oxytocin | Experimental | a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril. |
|
| placebo | Experimental | a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intranasal oxytocin | Drug | Subject assigned to receive intranasal administration of oxytocin (24 IU). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Behavioral index: fairness rating scores | Participants are instructed to rate their perceived levels of fairness to the allocation using a 9-point Likert scale within 4 seconds (1 = very unfair, 9 = very fair). | 45-75 minutes after treatment administration |
| Behavioral index: preference rating scores | Participants are instructed to rate their perceived levels of preference to the allocation using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very preferable). | 45-75 minutes after treatment administration |
| Neural indices: fMRI-based measures of the outcome presentation stage | Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are confronted with monetary allocations (advantageous-inequity, disadvantageous-inequity, and fair). | 45-75 minutes after treatment administration |
| Measure | Description | Time Frame |
|---|---|---|
| Behavioral index: choice rate of unequal option | Participants are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose. | 45-75 minutes after treatment administration |
| Neural indices: fMRI-based measures of outcome and re-decision stages |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yao Shuxia, Dr | University of Electronic Science and Technology of China | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Electronic Science and Technology of China (UESTC) | Chengdu | Sichuan | 611731 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intranasal placebo | Drug | Subjects assigned to receive intranasal administration of placebo (24 IU). |
|
Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose. |
| 45-75 minutes after treatment administration |